查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1986482

製藥連續生產市場報告：按治療領域、劑型、應用、最終用戶和地區分類（2026-2034 年）

Pharmaceutical Continuous Manufacturing Market Report by Therapeutics Type, Formulation, Application, End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球製藥連續生產市場規模達16億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到37億美元，2026年至2034年的複合年成長率（CAGR）為9.24%。北美憑藉其先進的技術基礎設施，在該市場中展現出明顯的優勢。此外，日益增強的健康意識和活性化的研發投入也推動了市場成長。同時，對高效製藥生產系統的需求不斷成長，也對市場產生了積極影響。

製藥連續生產市場正迅速發展，全球製藥業正不斷採用新技術來提高效率、品質和擴充性。永續性正成為製藥生產的關鍵考量因素，而連續生產系統與環保實踐相契合。能源消耗正在降低，原料利用效率正在提高，廢棄物產生量也正在減少。企業正在實施環保工藝，碳足跡正在縮小。連續生產支持製藥業對永續的承諾。隨著環境法規日益嚴格，製造商正在調整其業務運營，以符合全球永續性目標。這一趨勢進一步提升了連續生產流程的吸引力。

製藥連續生產市場的發展趨勢：

慢性病增多

全球慢性病（如糖尿病、心血管疾病、癌症和呼吸系統疾病）發生率的不斷上升，正推動製藥業採用連續生產技術。醫療系統不斷調整以應對日益成長的患者數量，製藥公司也相應地擴大產能。傳統的間歇式生產難以滿足救命藥物的持續需求，而連續生產則提供了更快、更經濟、更穩定的生產解決方案。這項技術能夠實現藥品不間斷的生產，確保供應能夠跟上不斷成長的治療需求。各公司也正致力於解決供不應求，提高藥品的可及性，特別是那些用於長期治療的基本藥物。根據國際糖尿病聯盟（IDF）最新發布的《糖尿病地圖集（2025）》，20至79歲的成年人中，11.1%（九分之一）患有糖尿病，超過40%的人對此毫不知情。隨著慢性病在已開發經濟體和新興經濟體的盛行率不斷上升，對經濟高效且擴充性的生產方式的需求也日益成長。連續生產透過穩定的品質和供應滿足了這一需求，確保患者始終能夠不間斷地獲得必需藥物。

技術創新與發展

隨著製藥公司不斷將自動化、人工智慧、數位雙胞胎和預測分析等技術融入生產流程，科技的快速發展正推動連續生產模式的普及。先進的過程控制系統能夠實現即時追蹤，機器學習演算法則可預測潛在偏差，從而最大限度地提高效率。這些進步帶來了更穩定的產品品質、更少的停機時間和更低的變異性。模組化系統結構提供了柔軟性，使工廠無需大規模重組即可適應多種規格的藥品。企業也在投資數位化平台，透過端到端的可追溯性，實現整個生產週期的完全透明。結合工業4.0技術，製藥生產正變得更加智慧、敏捷和有效率。這些技術正將連續生產確立為面向未來的製藥生產的支柱，幫助企業在滿足全球對價格合理、可靠且高品質的藥品日益成長的需求的同時，保持競爭力。根據IMARC Group預測，到2033年，全球工業4.0市場規模預計將達到5,705億美元。

監管機構的支持與鼓勵

監管機構正通過支持性指南、核准和框架，日益鼓勵連續生產。美國食品藥物管理局(FDA) 透過監管柔軟性來推動創新，而歐洲藥品管理局 (EMA) 和日本藥品和醫療設備管理局 (PMDA) 則致力於與全球標準接軌。這些機構正在為連續生產技術的快速普及鋪平道路，企業也積極響應，申請相關技術的核准。監管機構透過提供合規指導，鼓勵製藥公司採用即時品質監控、流程分析技術 (PAT) 和先進控制系統。這種支援降低了不確定性，加速了技術的普及，並增強了業界的信心。隨著更多核准的通過，法規環境對連續生產系統的信心也不斷增強。這種積極的態度正在推動小分子藥物、生物製藥和個人化醫療領域的應用，整個產業正逐步在全球範圍內向更廣泛地整合連續生產模式轉型。 2024 年，美國食品藥物管理局(FDA) 宣布，將於 2024 年 1 月 2 日至 3 月 1 日接受 START試驗計畫的申請，該計畫旨在加速罕見疾病治療藥物的研發。當研發項目達到與申辦方協議中規定的關鍵監管里程碑時，例如啟動主要臨床核准階段或達到上市前階段（生技藥品核准前或新藥認證前會議），該試點項目的申辦即被視為完成。

推動製藥連續生產市場成長要素：

降低成本和營運效益

由於其巨大的成本效益潛力和營運優勢，製藥業正逐步採用連續生產（MCM）。傳統的批次生產需要大量的空間、人力和較長的前置作業時間，而連續生產系統則能降低能耗、原料消耗和廢棄物產生。透過簡化製程，企業能夠降低生產成本，並在更少的生產週期內實現更高的產量。連續生產系統還能加速規模化生產，使製造商能夠更快地從研發階段過渡到大規模生產。在全球競爭日益激烈、藥品價格壓力不斷增大的環境下，這些優勢尤其重要。此外，連續生產還能透過縮小生產空間來降低基礎設施成本。透過維持產品品質的穩定性並最大限度地減少生產缺陷，企業可以避免代價高昂的延誤和召回。在一個力求在不犧牲安全性和品質的前提下，平衡藥品價格、合規性和病患可及性的產業中，這些營運效率的提升正成為推動產業發展的重要動力。

對生物製藥和先進療法的需求日益成長

隨著對生物製藥、生物相似藥以及細胞和基因療法等先進治療方法的需求快速成長，製藥業正日益轉向連續生產。傳統的間歇式生產流程已無法滿足這些治療方法的多樣化需求，而連續生產製程則能提供更高的一致性、效率和擴充性。企業正在採用連續上游工程（例如灌註生物反應器）和連續下游製程（例如層析法），以確保產品品質。這些方法縮短了生產週期，並加速了關鍵治療方法的上市。生物製藥產業也要求精確控制變異性，而連續系統透過實現即時監測和先進的控制機制來滿足這一需求。隨著全球對個人化和複雜治療方法的需求不斷成長，連續生產在滿足患者需求方面發揮主導作用。這種轉變使製藥業能夠有效地應對其最重要的促進因素之一。

人們越來越關注供應鏈韌性

在全球供應鏈動盪之後，製藥公司越來越重視供應鏈韌性，連續生產模式也因此得到日益廣泛的應用。傳統的大量生產通常依賴漫長的供應鏈和集中的製造地，因此極易出現延誤和供不應求。相較之下，連續生產模式能夠實現以本地為中心、分散化且靈活的生產模式，從而減少對複雜物流鏈的依賴。企業正在靠近患者的地方建立小規模模組化工廠，以確保患者能夠及時獲得藥物。這種策略降低了緊急情況下供應鏈中斷的風險，並增強了應對意外需求激增的能力。透過提高供應鏈的柔軟性，連續生產使製藥公司能夠更快地響應市場變化。在對供應鏈韌性日益重視的背景下，企業逐漸意識到更安全、更有效率、更永續的生產方案所蘊含的策略優勢，進而推動了連續生產模式的普及應用。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 調查方法

第3章執行摘要

第4章：引言

第5章：全球製藥連續生產市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療區域分類

  • 聚合物化合物
  • 低分子化合物

第7章 市場區隔：依劑型分類

  • 固態劑型
  • 液體和半固態製劑

第8章 市場區隔：依應用領域分類

  • 最終藥品生產
  • 原料藥（API）生產

第9章 市場區隔：依最終用戶分類

  • 製藥公司
  • 契約製造組織
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Baker Perkins
    • Coperion GmbH（Hillenbrand Inc.）
    • Eli Lilly and Company
    • GEA Group Aktiengesellschaft
    • Glatt GmbH
    • Korsch AG
    • Novartis AG
    • Siemens
    • SK biotek
    • Thermo Fisher Scientific Inc.
    • Viatris Inc.
Product Code: SR112026A5935

The global pharmaceutical continuous manufacturing market size reached USD 1.6 Billion in 2025 . Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2034 , exhibiting a growth rate (CAGR) of 9.24% during 2026-2034 . North America exhibits a clear dominance in the market due to its advanced technological infrastructure. Moreover, rising health concerns and increasing research and development (R&D) activities are propelling the market growth. Additionally, rising demand for effective medicine production systems is positively influencing the market.

The pharmaceutical continuous manufacturing market is experiencing rapid evolution, and the global industry is increasingly adopting new technologies to improve efficiency, quality, and scalability. Sustainability is becoming a critical consideration in pharmaceutical manufacturing, and continuous production systems are aligning with green initiatives. Energy consumption is decreasing, raw material usage is becoming more efficient, and waste generation is reducing. Companies are implementing environmentally friendly processes, and carbon footprints are shrinking. Continuous manufacturing is supporting the pharmaceutical industry's commitment to sustainable development. As environmental regulations are tightening, manufacturers are aligning operations with global sustainability goals. This trend is reinforcing the attractiveness of continuous processes.

PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET TRENDS:

Growing Prevalence of Chronic Disease

The global increasing incidence of chronic diseases like diabetes, cardiovascular disease, cancer, and respiratory disease is propelling the adoption of continuous manufacturing by the pharmaceutical sector. Healthcare systems are dealing with ever-increasing numbers of patients day by day, and pharma companies are reacting accordingly by increasing production capacity. Legacy batch operations are having a hard time keeping pace with unrelenting demand for life-saving pharmaceuticals, whereas continuous production is providing quicker, more economical, and more consistent solutions for manufacturing. In permitting unbroken output of medicines, this technology is guaranteeing that supply is meeting rising therapeutic demand. Firms are also emphasizing shortening shortages and enhancing availability, especially of significant medications prescribed in extended therapy. The most recent International Diabetes Federation (IDF) Diabetes Atlas (2025) indicates that 11.1%, equivalent to 1 in 9 of adults (aged 20-79) are affected by diabetes, with more than 40% being unaware of their condition. As chronic disease prevalence is rising in both developed and emerging economies, the need for cost-effective and scalable production is growing. Continuous manufacturing is meeting this need through consistent quality and quantity, such that patients are constantly receiving vital drugs without interruption.

Technological Innovations and Developments

Rapid technological advances are driving the adoption of continuous manufacturing, as pharma companies continue to infuse production processes with automation, artificial intelligence, digital twins, and predictive analytics. Sophisticated process control systems are facilitating real-time tracking, while machine learning algorithms are predicting potential drifts and maximizing efficiency. These advances are guaranteeing consistent quality of products, minimizing downtime, and reducing variability. Modular system architecture is providing flexibility, enabling buildings to fit in several drug sizes without extensive reorganization. Businesses are also making investments in digital platforms that are offering complete transparency throughout the production cycle with end-to-end traceability. Coupled with Industry 4.0 technologies, pharmaceutical production is becoming intelligent, agile, and quicker. These technologies are establishing continuous manufacturing as the pillar of future-proof pharmaceutical manufacture to help businesses stay competitive while fulfilling mounting world demand for affordable, dependable, and high-quality drugs. IMARC Group predicts that the global industry 4.0 market is expected to attain USD 570.5 Billion by 2033.

Regulatory Support and Encouragement

Regulatory bodies are increasingly encouraging continuous manufacturing through supportive guidelines, approvals, and frameworks. The U.S. Food and Drug Administration (FDA) is promoting innovation through regulatory adaptability, whereas the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are converging towards global standards. These agencies are opening routes to swift uptake, and the companies are reciprocating by requesting approvals for continuous manufacturing techniques. By providing guidance on compliance, regulators are encouraging pharmaceutical companies to implement real-time quality monitoring, process analytical technology (PAT), and advanced control systems. This assistance is reducing uncertainty, speeding adoption, and establishing industry confidence. With increasing case studies being approved, the regulatory environment is strengthening confidence in continuous systems. This positive attitude is propelling adoption in small-molecule medications, biologics, and the personalized medicine space, making the industry globally gradually move toward extensive integration of continuous manufacturing. In 2024, the U.S. Food and Drug Administration (FDA) declared that it will be accepting applications between Jan. 2, 2024, and March 1, 2024, for the START pilot program to accelerate the development of rare disease therapeutics. Sponsor engagement in the pilot will be deemed completed once the development program achieves a major regulatory milestone, like commencing the pivotal clinical trial phase or reaching the stage before filing a marketing application (pre-Biologics License Application or pre-New Drug Application meeting stage), as agreed with the sponsor.

PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET GROWTH DRIVERS:

Cost Savings and Operational Benefits

The pharmaceutical industry is progressively embracing continuous manufacturing due to its enormous cost-benefit potential and operational benefits. Conventional batch production is demanding big spaces, heavy manpower, and long timelines, while continuous systems are decreasing energy usage, reducing raw material use, and eliminating waste. Through process simplification, companies are lowering the cost of production and realizing more output in fewer cycles. Continuous systems are also facilitating quicker scale-up, making it possible for manufacturers to transition faster from development to full-scale manufacture. These advantages are especially crucial with competition heating up and drug pricing pressures building around the world. Continuous manufacturing is also enabling smaller manufacturing footprints, which is reducing infrastructure costs. In keeping quality constant and minimizing failures during production, companies are preventing expensive delays and recalls. This efficiency of operation is becoming a primary motivator, as the sector is always looking to reconcile affordability, compliance, and patient access without sacrificing safety or quality.

Increased Demand for Biopharmaceuticals and Advanced Therapies

The pharma industry is gravitating toward continuous manufacturing increasingly as demand for biologics, biosimilars, and advanced therapies like cell and gene therapies is increasing at a fast pace. Legacy batch processes are no longer adequate to handle the multifaceted demands of such treatments, while continuous processes are facilitating greater consistency, efficiency, and scalability. Firms are adopting continuous upstream processes like perfusion bioreactors, and continuous downstream methods like chromatography, to guarantee product quality. These approaches are minimizing cycle times and facilitating quicker market introduction for critical therapies. The biopharmaceutical industry is also calling for precise control of variability, and continuous systems are answering this call by enabling real-time monitoring and sophisticated control mechanisms. With an escalating global demand for personalized and complex treatments, continuous manufacturing is taking a leading role in serving patient needs. This change is making sure that the pharmaceutical industry is reacting to one of its most significant growth drivers effectively.

Increasing Emphasis on Supply Chain Resilience

Continuous manufacturing is increasingly being embraced by pharmaceutical firms as they focus on supply chain resilience due to global upheavals. Batch production is typically based on long supply chains and centralized plants, which are susceptible to delays and shortages. In contrast, continuous manufacturing is facilitating localized, decentralized, and flexible models of production that are diminishing dependence on elaborate logistics chains. Firms are adopting smaller, modular plants near patients to provide timely access to drugs. This strategy is also lowering risks of supply disruptions in cases of emergencies and enhancing the capacity to deal with unexpected spikes in demand. Through increased supply chain flexibility, continuous manufacturing is enabling pharmaceutical firms to respond more rapidly to changes in the marketplace. The growing focus on resilience is propelling companies towards the adoption of continuous manufacturing, as companies can now see the strategic benefit of more secure, responsive, and sustainable production schemes.

GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING INDUSTRY SEGMENTATION:

Breakup by Therapeutics Type:

  • Large Molecules
  • Small Molecules

Small molecules dominate the pharmaceutical continuous manufacturing market

Continuous manufacturing enhances efficiency and consistency in small-molecule drugs. Vertex Pharmaceuticals introduced Suzetrigine, a small molecule drug manufactured using continuous processes, optimizing production efficiency and ensuring consistent quality for pain management.

Breakup by Formulation:

  • Solid Formulation
  • Liquid and Semi-solid Formulation

Solid formulation currently holds most of the pharmaceutical continuous manufacturing market demand

Solid formulations, such as capsules and tablets, excel in continuous manufacturing due to improved consistency and efficiency. For example, XenoPharma's tablet production ensures uniform quality and scalable output, which is acting as another significant growth-inducing factor.

Breakup by Application:

  • Final Drug Product Manufacturing
  • API Manufacturing

Final drug product manufacturing dominates the market

Final drug product manufacturing in continuous processes ensures efficient production with consistent quality and scalability, thereby reducing waste and enhancing overall process control. It also results in cost savings. This is bolstering the pharmaceutical continuous manufacturing market revenue.

Breakup by End User:

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Others

Pharmaceutical companies hold most of the pharmaceutical continuous manufacturing market outlook

Pharmaceutical companies increasingly adopt continuous manufacturing to enhance efficiency, streamline production processes, and ensure consistent product quality. This is leading to faster and more cost-effective drug development.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest pharmaceutical continuous manufacturing market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

As per the pharmaceutical continuous manufacturing market research report, North America accounted for the largest share, driven by advanced drug delivery technologies. Moreover, regulatory bodies in the region are highly supportive of continuous manufacturing practices. The corporation with regulatory bodies encourages pharmaceutical companies to adopt continuous manufacturing solutions, thereby propelling the market growth. For instance, in May 2024, the U.S. Food and Drug Administration (FDA) introduced the START pilot program to catalyze the development of rare disease therapeutics.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market pharmaceutical continuous manufacturing companies have also been provided. Some of the key players in the market include:

  • Baker Perkins
  • Coperion GmbH (Hillenbrand Inc.)
  • Eli Lilly and Company
  • GEA Group Aktiengesellschaft
  • Glatt GmbH
  • Korsch AG
  • Novartis AG
  • Siemens
  • SK biotek
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

()

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the global pharmaceutical continuous manufacturing market?

2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2026-2034?

3. What are the key factors driving the global pharmaceutical continuous manufacturing market?

4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market growth?

5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?

6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?

7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?

8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?

9. What are the key regions in the global pharmaceutical continuous manufacturing market?

10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmaceutical Continuous Manufacturing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutics Type

  • 6.1 Large Molecules
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Small Molecules
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Formulation

  • 7.1 Solid Formulation
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Liquid and Semi-solid Formulation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Final Drug Product Manufacturing
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 API Manufacturing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Contract Manufacturing Organizations
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Baker Perkins
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Coperion GmbH (Hillenbrand Inc.)
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Eli Lilly and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 GEA Group Aktiengesellschaft
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Glatt GmbH
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Korsch AG
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Siemens
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 SK biotek
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Thermo Fisher Scientific Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Viatris Inc.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials

List of Figures

  • Figure 1: Global: Pharmaceutical Continuous Manufacturing Market: Major Drivers and Challenges
  • Figure 2: Global: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Therapeutics Type (in %), 2025
  • Figure 5: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Formulation (in %), 2025
  • Figure 6: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Application (in %), 2025
  • Figure 7: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Pharmaceutical Continuous Manufacturing (Others) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Pharmaceutical Continuous Manufacturing (Others) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: North America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: North America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: United States: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: United States: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Canada: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Canada: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: China: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: China: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Japan: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Japan: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: India: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: India: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: South Korea: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: South Korea: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Australia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Australia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Indonesia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Indonesia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Europe: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Europe: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Germany: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Germany: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: France: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: France: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: United Kingdom: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: United Kingdom: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Italy: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Italy: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Spain: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Spain: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Russia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Russia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Latin America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Latin America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Brazil: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Brazil: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Mexico: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Mexico: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Breakup by Country (in %), 2025
  • Figure 75: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Global: Pharmaceutical Continuous Manufacturing Industry: SWOT Analysis
  • Figure 77: Global: Pharmaceutical Continuous Manufacturing Industry: Value Chain Analysis
  • Figure 78: Global: Pharmaceutical Continuous Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pharmaceutical Continuous Manufacturing Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Therapeutics Type (in Million USD), 2026-2034
  • Table 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Formulation (in Million USD), 2026-2034
  • Table 4: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 5: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Pharmaceutical Continuous Manufacturing Market: Competitive Structure
  • Table 8: Global: Pharmaceutical Continuous Manufacturing Market: Key Players